Ensysce Biosciences, Inc. (ENSC)

NCM – Real Time Price. Currency in USD

0.40

-0.02 (-5.90%)

Market open: Aug 12, 2026, 1:27 PM EDT

0.41

-0.01 (-1.64%)

Previous after-hours: Aug 11, 2026, 7:58 PM EDT

06.08.2026

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Acquisition includes clinical-stage neuroplastogenic therapy with U.S. FDA Orphan Drug Designation for the treatment of Complex Regional Pain Syndrome (CRPS) Up to $77 million in private financing consisting of $21.5 million in private placement financing at initial close plus $17.1 million of Cy Biopharma's cash and cash equivalents from a pre-acquisition convertible note financing and up to $38.6 million upon achievement of clinical trial milestone Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept data and into registrational development SAN DIEGO, CA / ACCESS Newswire / August 6, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company") today announced it has completed the acquisition of Cy Biopharma, Inc. ("Cy Biopharma"), a privately held clinical-stage biotechnology company developing novel neuroplastogenic therapies beyond mood disorders, with an initial focus on complex pain. Concurrent with the acquisition that brought in $17.1 million in cash from a pre-acquisition convertible note financing, Ensysce entered into a definitive agreement for the sale of Series C non-voting convertible preferred stock (with a conversion ratio of preferred to common at 1:1,000) (the "Series C Preferred Stock") in a private placement financing, which is expected to result in gross proceeds to the Company of approximately $21.5 million at the initial close before deducting placement agent fees and other offering and transaction expenses, and includes up to a $38.6 million follow-on tranche that is expected to fund development of CY200 into 2028.

Videos

No Data

There is no data to display

Press releases

06.08.2026

Ensysce Biosciences, Inc. (ENSC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Videos

No Data

Press releases

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Videos

No Data

Press releases

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Search stocks

Ensysce Biosciences, Inc. (ENSC)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Ensysce Biosciences, Inc. (ENSC)

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Videos

No Data

Press releases

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Videos

No Data

Press releases

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing